Advances in Alzheimer’s disease management

2012 ◽  
pp. 2-3
Author(s):  
Serge Gauthier ◽  
Pedro Rosa-Neto
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Disease Management

Transdermal Drug Delivery Systems and their Potential in Alzheimer’s Disease Management

2020 ◽  
Vol 19 (5) ◽  
pp. 360-373 ◽  
Author(s):  
Panoraia I. Siafaka ◽  
Ece Ö. Bülbül ◽  
Gökce Mutlu ◽  
Mehmet E. Okur ◽  
Ioannis D. Karantas ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Drug Delivery ◽  
Alzheimer's Disease ◽  
Disease Management ◽  
Transdermal Drug Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Oral Dosage ◽  
Transdermal Administration ◽  
Transdermal Drug Delivery Systems

Alzheimer's disease is a neuropathological disease with symptoms such as language problems, confusion as to place or time, loss of interest in activities, which were previously enjoyed, behavioral changes, and memory loss. Alzheimer's disease and other types of dementia affect almost 46.8 million people globally and are estimated to strike about 131.5 million people in 2050. It has been reported that Alzheimer's is the sixth main cause of mortality. The most used drugs, which are currently approved by the Food, and Drug Administration for Alzheimer’s disease are donepezil, rivastigmine, galantamine, memantine, and the combination of donepezil and memantine. However, most of the drugs present various adverse effects. Recently, the transdermal drug delivery route has gained increasing attention as an emerging tool for Alzheimer's disease management. Besides, transdermal drug delivery systems seem to provide hope for the management of various diseases, due to the advantages that they offer in comparison with oral dosage forms. Herein, the current advancements in transdermal studies with potent features to achieve better Alzheimer's disease management are presented. Many researchers have shown that the transdermal systems provide higher efficiency since the first-pass hepatic metabolism effect can be avoided and a prolonged drug release rate can be achieved. In summary, the transdermal administration of Alzheimer's drugs is an interesting and promising topic, which should be further elaborated and studied.

Alzheimer's Disease Management Guideline: Update 2008

2011 ◽  
Vol 7 (3) ◽  
pp. e51-e59 ◽  
Author(s):  
Freddi Segal-Gidan ◽  
Debra Cherry ◽  
Randi Jones ◽  
Bradley Williams ◽  
Linda Hewett ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Disease Management ◽  
Management Guideline

Nanotechnology-based drug delivery systems for Alzheimer's disease management: Technical, industrial, and clinical challenges

2017 ◽  
Vol 245 ◽  
pp. 95-107 ◽  
Author(s):  
Ming Ming Wen ◽  
Noha S. El-Salamouni ◽  
Wessam M. El-Refaie ◽  
Heba A. Hazzah ◽  
Mai M. Ali ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Drug Delivery ◽  
Alzheimer's Disease ◽  
Disease Management ◽  
Drug Delivery Systems ◽  
Delivery Systems

Towards a Science of Alzheimer's Disease Management: A Model Based Upon Current Knowledge of Retrogenesis

1999 ◽  
Vol 11 (1) ◽  
pp. 7-23 ◽  
Author(s):  
Barry Reisberg ◽  
Sunnie Kenowsky ◽  
Emile H. Franssen ◽  
Stefanie R. Auer ◽  
Liduïn E. M. Souren
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Disease Management ◽  
Current Knowledge ◽  
Care Needs ◽  
Human Needs ◽  
Developmental Age ◽  
Age Model ◽  
Degenerative Dementia ◽  
Electroencephalographic Activity

Background: General relationships between dotage and infancy and childhood have been acknowledged for more than two millennia. Recent findings indicate precise relationships between functional, praxic, and feeding changes in the course of the degenerative dementia of Alzheimer's disease (AD) and inverse corresponding developmental sequences. Similar inverse relationships between AD and human development can be described for cognition and language skills; for physiologic measures of electroencephalographic activity, brain glucose metabolism, and developmental neurologic reflex changes; and for the neuropathologic and neuroanatomic progression of these processes. In AD, these processes may be termed “retrogenesis.” The relevance of the retrogenesis model for AD management is explored. Method: The functional stages of AD can be translated into developmental age equivalents that can be utilized to explicate observed changes in the disease. Results: The retrogenesis-based developmental age model can usefully inform an understanding of the general care needs, emotional and behavioral changes, and activity needs of the AD patient. This model must be amended by necessary caveats regarding physical differences, variations in age-associated pathology, differences in social and societal reactions, and differences in background between AD patients and their developmental age “peers.” Conclusions: Knowledge of retrogenesis and the developmental age of the AD patients can form a nidus for the development of a nascent science of disease management. Such a science must ultimately incorporate not only appropriate caveats but also relevant universal human needs, such as those for dignity, love, and movement.

scholarly journals Screening of Some Sulfonamide and Sulfonylurea Derivatives as Anti-Alzheimer’s Agents Targeting BACE1 and PPARγ

2020 ◽  
Vol 2020 ◽  
pp. 1-19
Author(s):  
Ning Li ◽  
Yan Wang ◽  
Wensheng Li ◽  
Haiyan Li ◽  
Liu Yang ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Disease Management ◽  
Virtual Screening ◽  
Physicochemical Properties ◽  
Binding Site ◽  
Docking Studies ◽  
Common Type ◽  
Beta Secretase ◽  
Agonistic Activity

In the last few decades, Alzheimer’s disease (AD) has emerged as a serious global problem, and it has been considered as the most common type of dementia. PPARγ and beta-secretase 1 (BACE1) are considered as potential targets for Alzheimer’s disease management. In the same time, sulfonylureas and sulfonamides have been confirmed to have PPARγ agonistic activity. Aiming to obtain new anti-AD agents, thirty-five compounds of sulfonamide and sulfonylurea derivatives having the same essential pharmacophoric features of the reported PPARγ agonists have been subjected to virtual screening. Docking studies revealed that five compounds (1, 2, 3, 4, and 5) have promising affinities to PPARγ. They were also docked into the binding site of BACE1. In addition, ADMET and physicochemical properties of these compounds were considered. Additionally, these compounds were further evaluated against BACE1 and PPARγ. Compound 2 showed IC50 value of 1.64 μM against BACE1 and EC50 value of 0.289 μM against PPARγ.

Sign in / Sign up

Export Citation Format

Share Document